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the use of function-specific single-chain antibody-MPIO 
conjugates for molecular MRI, and represent the first mo-
lecular imaging of a conformational change in a surface re-
ceptor. This presents an opportunity to specifically image 
activated   platelets   involved    in    acute    atherothrombosis    
with MRI.    Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Activated platelets adhere and aggregate rapidly at the 
site of arterial injury   [1]   and contribute to the pathogen-
esis of acute coronary syndromes  [2] . Anti-platelet agents 
are effective in reducing complications in a proportion of 
patients with acute ST-segment elevation myocardial in-
farction (MI)  [3, 4] , non-ST-segment elevation MI  [5]  and 
in the context of acute and high-risk percutaneous coro-
nary intervention   [6–8]  . However, the relative contribu-
tion of platelets varies in individual patients and accord-
ing to clinical circumstances  [9] . Therefore, precise deter-
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 Abstract 
 Ruptured atherosclerotic plaques, lined with activated plate-
lets, constitute an attractive target for magnetic resonance 
imaging (MRI). This study evaluated whether microparticles 
of iron oxide (MPIO) targeting ligand-induced binding sites 
(LIBS) on the activated conformation of glycoprotein IIb/IIIa 
could be used to image platelets. MPIO (size: 1    m)  were 
conjugated to anti-LIBS or control single-chain antibody. 
Following guidewire injury to mouse femoral artery, platelet 
adhesion was present after 24 h. Mice were perfused with 
anti-LIBS-MPIO (or control MPIO) via the left ventricle and 
11.7-tesla MRI was performed on femoral arteries ex vivo. A 
3D gradient echo sequence attained an isotropic resolution 
of 25   m. MPIO binding, quantified by MRI, was 4-fold high-
er with anti-LIBS-MPIO in comparison to control MPIO (p   !  
0.01). In histological sections, low signal zones on MRI and 
MPIO correlated strongly (R  2  = 0.72; p  !  0.001), indicating ac-
curate MR quantification. In conclusion, anti-LIBS-MPIO bind 
to activated platelets in mouse arteries, providing a basis for 
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mination of the presence and location of activated platelets 
would greatly aid in diagnosis and, potentially, provide 
the basis for an optimal choice of therapy.
  Recent progress in magnetic resonance imaging (MRI) 
has allowed detailed non-invasive determination of ath-
erosclerotic plaque composition and morphology   [10] . 
There is currently considerable interest in developing 
contrast ligand probes to enable imaging of specific mol-
ecules, cells and processes involved in atherothrombosis 
  [10, 11]  . Fibrin-rich thrombi have been targeted with 
paramagnetic nanoparticles conjugated to anti-fibrin 
F(ab) fragments   [12]   and with a fibrin-specific small 
molecule-gadolinium chelate   [13]  . Platelet-rich thrombi 
can be identified by coronary angioscopy   [9] .  Recently, 
exogenously labeled platelets have been imaged in surgi-
cally exposed large arteries using near infra-red micros-
copy in an animal model   [14]  . However, there is current-
ly no means to image platelets using non-invasive mo-
dalities, such as MRI.
    Shapiro et al.   [15]   recently described the use of mic-
roparticles of iron oxide (MPIO) for cellular imaging and 
tracking. These MPIO convey a payload of iron that is 
many orders of magnitude greater than iron nanoparti-
cles (ultrasmall particles of iron oxide) and cause local 
magnetic field inhomogeneity extending for a distance 
   50 times the physical diameter of the microparticle. We 
therefore hypothesized that with a suitable ligand, MPIO 
could be used for molecular imaging of activated plate-
lets. The platelet integrin GPIIb/IIIa (   IIb    3 , CD41/CD61) 
mediates the final common pathway of platelet aggrega-
tion and is the key to thrombus formation on ruptured 
atherosclerotic plaques. We have recently developed a 
s i n g l e - c h a i n  a n t i b o d y  t h a t  r e c o g n i z e s  l i g a n d - i n d u c e d  
binding sites (LIBS) of GPIIb/IIIa that become exposed 
only upon receptor activation and ligand binding  [16, 17] . 
The LIBS epitope is located outside the fibrinogen bind-
ing area and therefore yields high specificity for the acti-
vated GPIIb/IIIa receptor. Consequently, it can also be 
targeted even in the presence of fibrinogen or GPIIb/IIIa 
receptor antagonists. In contrast to non-activation-spe-
cific anti-GPIIb/IIIa antibodies, such as abciximab, the 
anti-LIBS single-chain antibody does not bind to circu-
lating platelets. It only binds to platelets which are acti-
vated by adhesion to inflamed or injured vessel walls or 
to activated platelets that are part of platelet aggregates 
  [16]  . Given its specificity, the anti-LIBS single-chain an-
tibody presents a compelling tool for molecular imaging 
of activated platelets with MRI.
    Accordingly, we have developed a contrast agent con-
sisting of anti-LIBS single-chain antibodies conjugated to 
MPIO and designed to target activated platelets. We re-
port here the capability of this contrast agent to identify 
activated platelets in a mouse model of endothelial injury 
  [18]   and accurate identification of MPIO binding using 
high-resolution ex vivo MRI.
  M e t h o d s  
  Single-Chain Antibody Generation and Conjugation to
1-   m Iron Oxide Microparticles 
  The monoclonal antibody anti-LIBS 145 binds to GPIIb/IIIa 
only in its active conformation and exhibits strong binding to 
ADP-activated platelets in the presence of fibrinogen   [17] .  The 
monoclonal antibody anti-LIBS 145 expressing hybridoma cell 
line was used as the basis for cloning of an anti-LIBS single-chain 
antibody (scFv). mRNA of this hybridoma cell line was prepared 
and reverse transcribed using an oligo-dT primer. The variable 
regions of the heavy and light chain of the antibody were ampli-
fied using PCR primers that anneal to conserved regions at the 5   
and 3   ends of the variable regions. The PCR products were cloned 
into the pHOG21 vector, TG1   Escherichia coli   were transformed, 
and individual clones were assessed for LIBS-typical binding to 
GPIIb/IIIa in flow cytometry using activated platelets. Finally, the 
best binding scFv  LIBS   was produced in LB media containing 100 
    g/ml ampicillin and 100 m  M   glucose at 37    °    C in 500-ml flasks. 
Cultures were shaken at 200 rpm for approximately 4–6 h until 
an OD (600 nm) of     0.8 was reached. Bacteria were pelleted by 
centrifugation at 5,000 rpm for 10 min at 4    °    C and resuspended 
with LB media containing 100   g/ml ampicillin and 0.4  M  sucrose 
(both Sigma, Deisenhofen, Germany). IPTG was added to a final 
concentration of 0.25 m  M   for induction of scFv production and 
incubated at room temperature (22–24    °    C) with 200 rpm for 16–
20 h. Bacteria were harvested by centrifugation at 5,000 rpm for 
10 min at 4    °    C, the pelleted bacteria were resuspended in 5 ml 1  !  
BugBuster     (Novagen, Freiburg, Germany) solution/g pellet and 
incubated for 15 min at room temperature with gentle shaking. 
After an additional centrifugation step at 15,000 rpm for 20 min 
at 4    °   C, the supernatant containing soluble protein was kept on ice 
and a protease inhibitor (Complete   ; Roche, Mannheim, Germa-
ny) diluted 1:     50 was added. The supernatant was mixed with 500 
   l Ni 2+  agarose (Qiagen, Hilden, Germany) and incubated for 1 h 
at 4    °   C with constant shaking at 150 rpm. Ni  2+  agarose, now bind-
ing His-tagged proteins, was allowed to settle for 30 min before 
being washed with buffer (50 m  M   NaH 2 PO 4 ,  300  m M   NaCl  and 
20 m  M   imidazole, pH 8). This batch washing procedure was re-
peated twice. Finally, the scFv was eluted at high imidazole con-
centrations (250 m  M  ) and finally dialyzed to PBS. Functionality 
of the scFv preparations was evaluated in flow cytometry.
    Cobalt-functionalized MPIO (1     m) were conjugated to the 
histidine tag of the LIBS single-chain antibody referring to the 
protocol of the manufacturer (Dynal-Beads TALON, Dynal Bio-
tech, Oslo, Norway; www.invitrogen.com/dynal). In brief, 1 mg of 
MPIO was incubated with the LIBS antibody for 10 min at room 
temperature to bind approximately 10     g of histidine-tagged an-
tibody. The tube containing the suspension was then placed on a 
magnet until the MPIO had migrated to the side of the tube, and 
the supernatant was discarded. This washing was repeated four   von zur Muhlen      et  al.
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times using a binding and washing buffer containing 50 m  M  NaP 
(pH 8), 300 m  M   NaCl and 0.01% Tween-20.
    LIBS-MPIO Binding to Activated Platelets 
  An adhesion assay was performed to demonstrate binding of 
the LIBS-MPIO to activated platelets. Since MPIO are visualized 
by light microscopy, they played a role analogous to that of the 
secondary antibody in immunohistochemistry. Blood from a 
healthy volunteer taking no medication was anticoagulated with 
citric acid and centrifuged at 1,000 rpm for 10 min. The resulting 
platelet-rich plasma was diluted with PBS (1:     10) and 100    l  were 
added onto fibrinogen-covered coverslips, which had been pre-
incubated with 20     g/ml fibrinogen for 1 h at 37    °    C and blocked 
with 1% bovine serum albumin (Sigma) for 1 h at room tempera-
ture. After a 30-min incubation at 37    °    C, coverslips were washed 
with PBS and under continuous rotation either incubated with 0.5 
    g of LIBS-MPIO or an equivalent conjugated irrelevant single-
chain antibody control (control MPIO) for another 30 min at 
37    °    C. Coverslips were then washed twice for 5 min with PBS and 
blocked with 10% goat serum (Vector, Burlingame, Calif., USA) 
for 1 h at room temperature. Due to red autofluorescence of the 
MPIO, LIBS-MPIO and control MPIO contrast agent could be 
readily identified by confocal microscopy. To demonstrate spe-
cific binding of the contrast agent, platelets were co-stained for 
P-selectin using a monoclonal mouse anti-human CD62 antibody 
(1:     100, R&D Systems, Abingdon, UK) with a biotinylated goat 
anti-mouse IgG (Vector, Burlingame, Calif., USA) serving as a 
secondary antibody. Finally, fluorescein avidin D (Vector) diluted 
1:    200 was added and incubated for 1 h at room temperature. Cov-
erslips were fixed using CellFix (BD Biosciences, Heidelberg, Ger-
many) and evaluated by confocal microscopy.
  M i c e  
  Wire injury was performed in male C57BL/6 mice (Jackson 
Laboratories, Margate, UK), mean age 10   8   0.8 weeks. Mice re-
ceived water and standard chow diet ad libitum. All procedures 
were performed in accordance with the    UK Home Office Animals 
(Scientific Procedures) Act 1986.
    Femoral Wire Injury, MPIO Perfusion and Sample 
Preparation ex vivo 
  Single-sided femoral wire injury was performed under general 
anesthesia in 13 mice, using a combination of Hypnorm (25 mg/kg, 
Bayer, Leverkusen, Germany) and Hypnoval (25 mg/kg, Bayer) ad-
ministered subcutaneously, as described previously   [18]  . Under a 
surgical microscope, a groin incision was made. The femoral artery 
was exposed, and an arteriotomy was made distal to the epigastric 
branch using a 30-gauge injection cannula (BD, Erembodegem, 
Belgium). A 0.010’ guidewire (Boston Scientific, Natick, Mass., 
USA) was inserted, advanced to the aortic bifurcation, and pulled 
back. After removal of the wire, the arteriotomy site was ligated and 
the skin closed using silk sutures. After 24 h, mice were terminally 
anesthetized by inhalation of isoflurane. The chest was opened by 
thoracotomy, the heart exposed and the right atrium cut. A 30-
gauge needle was inserted through the apex of the left ventricle and 
the animal was perfused with 10 ml of PBS to eliminate the blood. 
Perfusion was continued with 5 ml of PBS containing either LIBS-
MPIO or control-MPIO (1.5  !  10 8  MPIO/ml for each, correspond-
ing to approximately 6.5 mg iron/kg body weight): 7 mice were 
perfused with LIBS-MPIO and 6 with control MPIO via the left 
ventricle. After 30 min, mice were again perfused under physiolog-
ical pressure with 10 ml of PBS followed by 5 ml of 4% paraformal-
dehyde containing 2 m  M   gadoteridol (Prohance, Bracco, UK).
  After perfusion, the skin was removed, the leg with the area of 
injury cut, kept in 4% paraformaldehyde/2 m  M   gadoteridol  for
24 h and then embedded in a glass MR tube containing 2%
high-grade, low-melting-point agarose (Cambrex, Rockland, Me., 
USA).
  Ex  vivo  MRI 
  Ex vivo MRI was performed at 11.7 T (Bruker BioSpin 500 
MHz, Bruker, Coventry, UK) using a 13-mm   1  H birdcage radio-
frequency coil (RAPID Biomedical, Würzburg, Germany). A 3D 
gradient echo sequence (TE = 4 ms/TR = 90 ms, field of view 
13   !   13  !  19.5 mm, matrix size 256  !  256  !  384, two averages, 
imaging time     7 h/sequence) was used in an unattended over-
night run. The MRI sequence employed provided T  2 -weighted 
images that are typically used for the identification of iron-based 
contrast agents   [19]  . Data reconstruction was performed off-line 
with a final isotropic resolution of 25    m.
    Histology and Quantification of MPIO Binding in the Injured 
Femoral Artery 
  After MRI, specimens were decalcified in 10% formic acid 
overnight, dehydrated through graded ethanol solutions and 
Neo-clear (VMR, UK), paraffin embedded and serially sectioned 
(8   m thick). Specimens were stained for iron (Accustain, Sigma) 
referring to the manufacturer’s protocol. The number of conju-
gated MPIO bound to the injured luminal vessel wall was quanti-
fied and averaged in 20–25 sections from the injured vessel per 
animal site using light microscopy.
    For platelet visualization with immunohistochemistry, depa-
raffinized and rehydrated sections were saturated in 1% H  2 O 2  for 
20 min, added to simmering citrate buffer and boiled for 4 min in 
a pressure cooker for antigen retrieval. Specimens were washed in 
PBS/Tween-20, incubated with protein block solution (DakoCy-
tomation, Hamburg, Germany) for 4 h and incubated overnight 
at 4    °    C with rat anti-mouse CD61 antibody (1:    8,000,  InterCell 
Technologies, Jupiter, Fla., USA). After washing with PBS, a bio-
tinylated goat anti-rat IgG (1:     200, Vector, Burlingame, Calif., 
USA) secondary antibody was used. Slides were washed with PBS, 
and a peroxidase reaction was performed using Vectastain RTU 
Elite ABC reagent and Vector NovaRed (both Vector). Finally, 
sections were dehydrated and mounted with Permount (Biomeda, 
Foster City, Calif., USA), and MPIO binding to platelets was eval-
uated on a light microscope.
    MPIO Binding in the Femoral Artery by ex vivo MRI 
  Quantification of MPIO binding was performed blind to the 
origin of the image. Antibody-conjugated MPIO binding was de-
fined as an intense circular signal void (appearing as black circular 
areas, marked with arrows in   fig. 2  a) on the luminal surface of the 
femoral artery in   6  2 consecutive slices. MPIO appearing in mul-
tiple sections were counted only once. The region of interest in each 
animal started directly proximal to the perforating branch of the 
femoral artery, and MPIO-induced signal void was quantified in 
150 consecutive slices for each artery. MPIO binding is presented 
as low-signal areas per artery. Segmented images were reconstruct-
ed in three dimensions using the 3D Constructor plug-in for Im-
agePro Plus to visualize the distribution of MPIO binding through-  MRI of Activated Platelets  J Vasc Res 2009;46:6–14 9
out the femoral artery, with the low-signal area assigned to the red 
channel and the anatomical image to the green channel.
    Biodistribution of MPIO in vivo 
 Live mice (n = 3 per group) were injected with LIBS-MPIO via 
the tail vein in a dose of 4   !   10 8   MPIO in total (4.5 mg iron/kg 
body weight), since we successfully applied this dose of MPIO in 
previous experiments of in vivo VCAM imaging   [20, 21] .  One 
group of animals was sacrificed after 30 min, and the other group 
after 24 h. Frozen sections of lungs, liver, kidneys and spleen were 
obtained (slice thickness 10   m) using a standard protocol. MPIO 
distribution was quantified on a microscope in five high-power 
(100 !  ) fields of view per organ to obtain a mean for each animal. 
No staining of the sections was necessary, since MPIO could be 
easily identified in tissues due to their typical appearance.
  S t a t i s t i c a l   M e t h o d s  
  Data are expressed as means   8   SEM. Parametric data were 
compared using t tests. Statistical significance was assigned to 
p   !   0.05.
  R e s u l t s  
  LIBS-MPIO Detect Activated GPIIb/IIIa Receptors on 
Platelets 
  In   figure 1  a, layers of human platelet aggregates la-
belled with anti-P-selectin antibody show bright green 
fluorescence. Superimposed on these platelet aggregates 
are red particles, corresponding to fluorescent LIBS-
MPIO (online version). In  figure 1 b, these MPIO are con-
fined to the platelet aggregates without non-specific 
background retention. By contrast, there is absence of 
binding of control MPIO conjugated to an irrelevant sin-
gle-chain antibody. In   figure 1  c, the z-stack reconstruc-
tion in confocal microscopy shows LIBS-MPIO binding 
(red, online version) to P-selectin-stained platelets (green, 
online version), emphasizing their relative size and spa-
tial relations and the presence of multiple LIBS-MPIO on 
platelet clusters.
    LIBS-MPIO Bound to Wall-Adherent Platelets 
Detected by ex vivo MRI 
  Unilateral femoral artery wire injury was performed 
in mice without complication. One control animal was 
excluded from the quantification analysis, due to marked 
variation in the MRI quantification of MPIO between 
two observers.
  E x   v i v o   T  2  -weighted MRI of injured arterial segment 
typically demonstrated intrinsic multiple low-signal ar-
eas within the arterial wall (  fig. 2  b). In contrast, circular 
intense signal voids emerged within the vessel lumen, ad-
jacent to the vessel wall. In some cases, the ‘bloom’ effect 
due to distortion of the local magnetic field extended far 
beyond the physical space occupied by MPIO, and caused 
encroachment of the contrast effect into the vessel wall. 
These features were observed in the wire-injured arteries 
of all mice injected with LIBS-MPIO (  fig. 2  a). In quanti-
tative analysis, luminal areas of low signal, suggesting 
MPIO accumulation, were     4-fold higher in LIBS-
MPIO-injected animals than in control-MPIO-perfused 
animals (values given as total number of round circular 
signal void per animal; 23.72 vs. 6.2, p   !   0.01;   fig.  2 d).
    MPIO binding was confirmed in histology. MPIO 
have a typical appearance under the microscope as arti-
ficially round structures. Depending upon the focus used 
1 μm
5 μm 5 μm ab
c
  Fig. 1.   Confocal microscopy of human platelets immobilized on 
fibrinogen and detected by anti-CD62 antibody, shown with avi-
din-fluorescein immunofluorescence (  a–c  : green in the online 
version). Platelets incubated with the autofluorescent LIBS-MPIO 
contrast agent (  a ,  c  : red in the online version) show specific bind-
ing to platelets (  a  ). Incubation of platelets with control-MPIO 
contrast agent shows no MPIO binding (  b  ). 3D rendering of 
stained platelets incubated with LIBS-MPIO: multiple LIBS-
MPIO binding to clusters of activated platelets via GPIIb/IIIa (  c ).   von zur Muhlen      et  al.
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on the microscope, they can appear as round structures 
with a green, blue or red center and a halo of brown or 
black color (  fig. 3  a–c, online version). The MPIO were 
clearly distinguishable from natural tissue structures or 
wall-adherent cells (  fig. 3  a, c), and staining for iron was 
negative. The absence of specific iron staining can be at-
tributed to the impervious polystyrene shell that effec-
tively insulated the iron oxide core. This effect of negative 
iron stain of MPIO was unexpected, however, we decided 
to continuously apply iron stain to our sections as tissue 
structures were easily detectable, and as we were simul-
taneously able to exclude other iron accumulations than 
MPIO responsible for our signal effect (clots of red blood 
cells).
    MPIO quantification on the vessel surface of LIBS-
MPIO- and control-MPIO-perfused animals showed a 
significantly higher binding for LIBS-MPIO compared to 
control MPIO (9.98 vs. 0.5 MPIO/section, p  !  0.01;  fig.  3 a, 
200 μm 200 μm 200 μm
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  Fig. 2.  Ex vivo MRI at 11.7 T. 3D gradient echo sequence (TR = 90 
ms, TE = 4 ms, imaging time 7 h and resolution 25    m  isotropic). 
  a   The injured femoral artery exposed to LIBS-MPIO shows mul-
tiple, intensely-low-signal, lobulated areas at the interface be-
tween vessel wall and lumen (arrows). In the injured artery per-
fused with control-MPIO (  b  ), there is a small amount of inherent 
signal heterogeneity, but this is clearly distinguished from the ap-
pearance of bound contrast (  a  ). The same is true for the example 
of an uninjured artery without MPIO perfusion, which yields sig-
nal effects comparable to the injured vessel in   b  . Areas of signal 
void were quantified in total for every artery (  d ).  Quantification 
of MPIO-induced MRI signal voids revealed a significant differ-
ence between LIBS-MPIO- and control-MPIO-perfused mice
(p   !   0.05). 
a
b
c
0
MPIO
bound
(n/sec
tion)
LIBS-MPIO d Control MPIO
14
p < 0.01
2
4
6
8
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12
  Fig. 3.   Histology of representative injured femoral artery seg-
ments.    a   Multiple MPIO binding to the injured wall after perfu-
sion with LIBS-MPIO (arrows).   b   In contrast, no binding can be 
observed after control-MPIO perfusion.   c   The arterial wall and 
surrounding tissue appears red (online version) due to the para-
rosaniline stain contained in the standard protocol of iron stain-
ing. Co-localization of LIBS-MPIO contrast agent and platelets 
was confirmed using immunohistochemistry for CD61; single 
platelets can be seen as rust-colored (online version) structures 
with NovaRed (marked with arrows).   d   Quantification of MPIO 
bound per section in LIBS-MPIO- and control-MPIO-perfused 
mice, showing highly specific binding of the LIBS-targeted con-
trast agent (p       !   0.01).   MRI of Activated Platelets  J Vasc Res 2009;46:6–14 11
b, d). Co-localization of LIBS-MPIO and platelets adher-
ent to the arterial wall was confirmed by immunostain-
ing for the platelet marker CD61 (  fig. 3  c).
    Analysis of MPIO quantification in histology com-
pared to quantification by ex vivo MRI revealed a strong 
correlation (R  2   = 0.7219, p   !   0 .00 1 ;   fi g .  4  ) .  Th e r ef o r e, 
MPIO signal quantity, determined by MRI, directly re-
flected the quantity of MPIO bound to the injured vessel 
wall. To appreciate the binding patterns of MPIO within 
an injured segment, 3D reconstruction of segmented im-
ages was undertaken. In  figure 5 , structures appearing as 
MPIO-induced signal void were encoded by a red color, 
and for the vessel lumen a green color was chosen (online 
version). Bright red spots correspond to areas of intense 
0
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emoral)
10
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40
0 5 1 01 52 02 5
Histology (MPIO/section)
  Fig. 4.   Quantification of MPIO binding. Quantification of MPIO 
signal per injured leg by MRI and histological analysis were 
strongly correlated (R  2   =   0 . 7 2 ;   p                !   0.001). 
200 μm 200 μm 200 μm a b c
  Fig. 5.   Three-dimensional  reconstruction 
of the femoral artery of an anti-LIBS-
MPIO-injected mouse. (Online version 
o n l y :       a  In this reconstruction, the anatom-
ical image has been allocated to the green 
channel. Therefore, the femoral artery lu-
men appears as a green tube.   b   Segmented 
regions of contrast were allocated to the 
red channel).   c   The merged image shows 
diffuse and relatively even MPIO binding 
along the luminal surface of the injured 
vessel segment. The magnetic field distor-
tion of MPIO reaches beyond their physi-
cal diameter, therefore MPIO contrast ef-
fects  extend  into  the  vessel  wall.       
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  Fig. 6.  In vivo biodistribution. MPIO were quantified in the lung, 
kidney, liver and spleen, 30 min and 24 h after intravenous ad-
ministration. Retention by the lungs is minimal at either time 
point. By contrast, there was rapid uptake by the spleen and liver. 
Efficient removal of contrast agent from the circulation is advan-
tageous for in vivo imaging, where background blood MPIO may 
o t h e r w i s e   o b s c u r e   s p e c i f i c a l l y   b o u n d   c o n t r a s t .                    von zur Muhlen      et  al.
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low signal and are seen scattered throughout this injured 
arterial segment. As the MPIO contrast effect extends be-
yond the physical limit of the particle (    50 times the 
physical diameter), it appears that some red spots are par-
tially located within, even beyond, the vessel wall (online 
version). Furthermore, it is possible that not every spot 
represents a single MPIO, but can also be caused by co-
localized MPIO on a platelet surface.
    Biodistribution of MPIO in vivo 
  All mice tolerated MPIO injection and showed no 
signs of ill health up to 24 h after injection. MPIO were 
identified in the lung, kidney, liver and spleen after 30 
min and 24 h (  fig. 6  ). Even at the early time points, there 
was minimal retention by the lungs (at 30 min, lung: 6.9 
MPIO/section vs. spleen: 110 MPIO/section; p   !   0.001). 
As expected, the bulk of the MPIO load was rapidly se-
questered by the liver and the spleen (liver: 31.8 MPIO/
section; spleen: 110 MPIO/section; p   !   0.001 vs. MPIO/
section in the lung and kidneys at 30 min).
  Discussion 
  Imaging platelet thrombi is of considerable interest to 
aid in diagnosis and guide therapy in acute vascular syn-
dromes. We report the development and application of a 
molecular contrast agent that targets activated platelets 
and enables quantification of contrast binding using 
MRI. We have used a single-chain antibody that recog-
nizes only the active conformation of GPIIb/IIIa, and 
therefore confers both molecular and functional specific-
ity. To the best of our knowledge, this is the first report 
on functional MRI of a cellular surface molecule accord-
ing to its conformational state. Secondly, we have exploit-
ed the fact that intravascular structures are accessible to 
1-   m-sized particles that are     orders of magnitude larger 
than the iron oxide nanoparticles used previously for 
similar applications. This approach has provided excep-
tionally conspicuous contrast on MRI.
    As no reliable animal model of plaque rupture exists, 
we used mouse femoral wire injury to induce platelet 
thrombi. The time course of cellular events following 
femoral wire injury in this model is well described and 
consistently shows confluent platelet deposition on the 
denuded endothelium after 24 h (  fig. 3  c)   [18] .  We  used 
this as the basis for targeting activated platelets with 
  single-chain antibodies against LIBS on the activated 
GPIIb/IIIa receptor. This antibody confers   functional  
specificity since its binding is dependent upon the pres-
ence of the activated form of GPIIb/IIIa  [17] . These prop-
erties make LIBS a unique target to mediate MPIO at-
tachment to platelet thrombi. The targeting potency of 
the anti-LIBS single-chain antibody has been recently 
demonstrated by the strong enrichment of an anticoagu-
lant effector molecule at clots  [16] . Following left-ventric-
ular injection, LIBS-MPIO bound specifically to platelet 
thrombi in the femoral artery. Using a T  2 -weighted  MRI 
sequence, signal voids corresponding to MPIO binding 
were quantified. The extent of signal extinction caused 
by the MPIO in T  2  -weighted MRI corresponded to the 
MPIO number on histology.
    A limitation of the current study is the absence of in 
vivo imaging. Following intravenous injection, we have 
n o t  b e e n  a b l e  t o  d e m o n s t r a t e  a c c u m u l a t i o n  o f  L I B S -
MPIO on the walls of the injured femoral artery (data not 
shown). This may be explained by the type of injury mod-
el used in our study. The model of femoral artery wire 
injury is known to result in a thin monolayer of platelets 
on the injured arterial wall   [18, 22]  . Thus, only a few tar-
geting epitopes are exposed. Furthermore, it is known 
that arterial shear stress in the femoral artery is high and 
thus the limited number of epitopes may not be sufficient 
to enable adhesion of the 1-    m MPIO. It is also known 
from leukocyte biology that to effect binding to the en-
dothelium under flow conditions is a complex biological 
task requiring the interaction of multiple receptors   [23–
25] . Indeed, single ligand binding to either VCAM-1 or to 
P-selectin resulted in modest retention of MPIO, which 
was markedly increased by the combination of ligands 
against both VCAM-1 and P-selectin   [20] .  However,  the 
application of MPIO-based contrast agents is a promising 
strategy for in vivo imaging, as we recently showed by 
targeting VCAM in acute brain inflammation with a 
VCAM-targeted MPIO   [21]  . Therefore, the size of the 
MPIO does not seem to be a limitation for the successful 
binding of the contrast agent to the epitope, but the mod-
el of a platelet monolayer applied in this study is subopti-
mal. Thus, while the current experiments show proof of 
principle, limitations of the specific model mean that in 
vivo imaging remains to be demonstrated, potentially in 
a different vessel with larger thrombi.
    Previous targeted contrast agent approaches have in-
cluded integrin-targeted gadolinium-rich perfluorocar-
bon nanoparticles   [26] ,  peptide-conjugated  nanoparti-
cles of iron oxide   [27]   and fibrin-specific cyclic peptides 
labelled with gadolinium   [13]  . However, the quantity of 
contrast agent that can be delivered, and therefore the 
intensity of contrast effect achieved, is relatively limited, 
particularly for low-abundance targets. Iron micropar-  MRI of Activated Platelets  J Vasc Res 2009;46:6–14 13
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    A strength of MPIO use for in vivo imaging is their 
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  Conclusion 
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